Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05932667
Title Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer (DEMETER)
Acronym DEMETER
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Institut Curie
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Additional content available in CKB BOOST